ArticleScience China. Life sciences2018
A novel human mAb (MERS-GD27) provides prophylactic and postexposure efficacy in MERS-CoV susceptible mice.
Article in Science China. Life sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Structural Basis of MERS-CoV Receptor Interactions and Antibody Neutralisations.Reviews in medical virology · 2026Review
- Harnessing immunotherapeutic molecules and diagnostic biomarkers as human-derived adjuvants for MERS-CoV vaccine development.Frontiers in immunology · 2025Review
- A highly susceptible hACE2-transgenic mouse model for SARS-CoV-2 research.Frontiers in microbiology · 2024Article
- Neutralizing monoclonal antibodies against highly pathogenic coronaviruses.Current opinion in virology · 2022Review
- The structure of a novel antibody against the spike protein inhibits Middle East respiratory syndrome coronavirus infections.Scientific reports · 2022Article
- Molecular evidence suggesting the persistence of residual SARS-CoV-2 and immune responses in the placentas of pregnant patients recovered from COVID-19.Cell proliferation · 2021Article
- Enhancing oxygenation of patients with coronavirus disease 2019: Effects on immunity and other health-related conditions.World journal of clinical cases · 2021Review
- Potent germline-like monoclonal antibodies: rapid identification of promising candidates for antibody-based antiviral therapy.Antibody therapeutics · 2021Article
- Clinical characteristics of coronavirus disease 2019 (COVID-19) in patients out of Wuhan from China: a case control study.BMC infectious diseases · 2021Article
- Model Prediction for In-Hospital Mortality in Patients with COVID-19: A Case-Control Study in Isfahan, Iran.The American journal of tropical medicine and hygiene · 2021Article
- Development of Coronavirus Treatments Using Neutralizing Antibodies.Microorganisms · 2021Review
- The preliminary comparative results between Covid-19 and non-Covid-19 patients in Western China.BMC infectious diseases · 2020Article
- Viral sepsis is a complication in patients with Novel Corona Virus Disease (COVID-19).Medicine in drug discovery · 2020Article
- Nanomedicine strategies to target coronavirus.Nano today · 2020Review
- SARS-CoV-2: A comprehensive review from pathogenicity of the virus to clinical consequences.Journal of medical virology · 2020Review
- Lack of antibody-mediated cross-protection between SARS-CoV-2 and SARS-CoV infections.EBioMedicine · 2020Article
- Elevated plasma levels of selective cytokines in COVID-19 patients reflect viral load and lung injury.National science review · 2020Article
- Coronavirus infections and immune responses.Journal of medical virology · 2020Review
- Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury.Science China. Life sciences · 2020Article
- Repurposing Drugs, Ongoing Vaccine, and New Therapeutic Development Initiatives Against COVID-19.Frontiers in pharmacology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.